Citigroup Boosts Danaher (NYSE:DHR) Price Target to $290.00

Danaher (NYSE:DHR) had its target price hoisted by Citigroup from $280.00 to $290.00 in a research report report published on Wednesday, Benzinga reports. Citigroup currently has a buy rating on the conglomerate’s stock.

DHR has been the subject of several other reports. Royal Bank of Canada lifted their price objective on shares of Danaher from $254.00 to $282.00 and gave the stock an outperform rating in a research note on Wednesday, January 31st. TD Cowen lifted their target price on Danaher from $280.00 to $290.00 and gave the stock a buy rating in a research report on Wednesday. Robert W. Baird lifted their target price on Danaher from $259.00 to $271.00 and gave the stock an outperform rating in a research report on Wednesday. KeyCorp lifted their target price on Danaher from $260.00 to $290.00 and gave the stock an overweight rating in a research report on Thursday, February 1st. Finally, Bank of America lifted their target price on Danaher from $258.00 to $270.00 and gave the stock a neutral rating in a research report on Wednesday. Six analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, Danaher currently has an average rating of Moderate Buy and an average price target of $270.00.

Danaher Stock Up 0.3 %

NYSE DHR opened at $246.45 on Wednesday. The company has a quick ratio of 1.37, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. The company has a fifty day moving average of $248.87 and a two-hundred day moving average of $231.08. The firm has a market capitalization of $182.54 billion, a price-to-earnings ratio of 41.77, a PEG ratio of 3.78 and a beta of 0.83. Danaher has a 52 week low of $182.09 and a 52 week high of $259.00.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. Danaher’s quarterly revenue was down 2.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.36 earnings per share. On average, analysts predict that Danaher will post 7.65 earnings per share for the current year.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 26th. Investors of record on Thursday, March 28th were issued a $0.27 dividend. This is an increase from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. The ex-dividend date of this dividend was Wednesday, March 27th. Danaher’s payout ratio is presently 18.31%.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the completion of the transaction, the senior vice president now directly owns 4,244 shares in the company, valued at $1,029,891.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Danaher news, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the completion of the transaction, the senior vice president now directly owns 4,244 shares in the company, valued at $1,029,891.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the transaction, the senior vice president now owns 38,102 shares of the company’s stock, valued at $9,601,704. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 106,565 shares of company stock worth $26,641,364. 11.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Danaher

A number of large investors have recently added to or reduced their stakes in the company. Banco Santander S.A. purchased a new stake in shares of Danaher during the third quarter worth about $683,000. First Citizens Bank & Trust Co. grew its stake in shares of Danaher by 0.6% during the fourth quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock worth $6,156,000 after acquiring an additional 149 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Danaher by 48.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock worth $68,707,000 after acquiring an additional 96,395 shares during the last quarter. Parkside Financial Bank & Trust grew its stake in shares of Danaher by 4.8% during the third quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate’s stock worth $764,000 after acquiring an additional 142 shares during the last quarter. Finally, Keybank National Association OH grew its stake in shares of Danaher by 0.5% during the third quarter. Keybank National Association OH now owns 553,155 shares of the conglomerate’s stock worth $137,238,000 after acquiring an additional 2,567 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.